NCT01657214View on ClinicalTrials.gov

Phase I, Dose Escalation of SAR125844 in Asian Solid Tumor Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Neoplasm Malignant
Interventions
DRUG

SAR125844

"Pharmaceutical form:Concentrate for solution~Route of administration: intravenous"

Trial Locations (8)

Unknown

Investigational Site Number 392001, Kashiwa-Shi

Investigational Site Number 392004, Suita-Shi

Investigational Site Number 392002, Sunto-Gun

Investigational Site Number 392003, Takatsuki-Shi

110-744

Investigational Site Number 410001, Seoul

120-752

Investigational Site Number 410004, Seoul

135-710

Investigational Site Number 410003, Seoul

138-736

Investigational Site Number 410002, Seoul

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT01657214 - Phase I, Dose Escalation of SAR125844 in Asian Solid Tumor Patients | Biotech Hunter | Biotech Hunter